Cite
Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
MLA
O’Shaughnessy, J. A., et al. “Prospective, Randomized Trial of 5-Fluorouracil, Leucovorin, Doxorubicin, and Cyclophosphamide Chemotherapy in Combination with the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Fusion Protein (PIXY321) versus GM-CSF in Patients with Advanced Breast Cancer.” Blood, vol. 87, no. 6, Mar. 1996, pp. 2205–11. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=8630380&authtype=sso&custid=ns315887.
APA
O’Shaughnessy, J. A., Tolcher, A., Riseberg, D., Venzon, D., Zujewski, J., Noone, M., Gossard, M., Danforth, D., Jacobson, J., Chang, V., Goldspiel, B., Keegan, P., Giusti, R., & Cowan, K. H. (1996). Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood, 87(6), 2205–2211.
Chicago
O’Shaughnessy, J A, A Tolcher, D Riseberg, D Venzon, J Zujewski, M Noone, M Gossard, et al. 1996. “Prospective, Randomized Trial of 5-Fluorouracil, Leucovorin, Doxorubicin, and Cyclophosphamide Chemotherapy in Combination with the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Fusion Protein (PIXY321) versus GM-CSF in Patients with Advanced Breast Cancer.” Blood 87 (6): 2205–11. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=8630380&authtype=sso&custid=ns315887.